Form 8.3 - AGI Therapeutics Plc (1579W)
25 Janvier 2012 - 1:41PM
UK Regulatory
TIDMAGI
RNS Number : 1579W
Peel Hunt LLP
25 January 2012
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH
TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2007 (AS AMENDED)
DEALINGS BY PERSONS WITH INTERESTS
IN RELEVANT SECURITIES REPRESENTING
1% OR MORE
1. KEY INFORMATION
=================================================================
Name of person dealing Peel Hunt LLP
(Note 1)
============================= ==================================
Company dealt in AGI Therapeutics
Plc
============================= ==================================
Class of relevant Ordinary Shares of
security to which EUR0.01 each
the dealings being
disclosed relate
(Note 2)
============================= ==================================
Date of dealing 24 January 2012
============================= ==================================
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions
(following dealing) in the class of
relevant security dealt in (Note 3)
=================================================================
Long Short
============================= =============== =================
Number (%) Number (%)
============================= =============== =================
3,447,294
(1) Relevant securities (5.11%)
============================= =============== =================
(2) Derivatives
(other than options)
============================= =============== =================
(3) Options and
agreements to purchase/sell
============================= =============== =================
3,447,294
Total (5.11%)
============================= =============== =================
(b) Interests and short positions
in relevant securities of the company,
other than the class dealt in (Note
3)
=================================================================
Class of relevant Long Short
security:
============================= =============== =================
Number (%) Number (%)
============================= =============== =================
(1) Relevant securities
============================= =============== =================
(2) Derivatives
(other than options)
============================= =============== =================
(3) Options and
agreements to purchase/sell
============================= =============== =================
Total
============================= =============== =================
1 February 2009
3. DEALINGS (Note 4)
(a) Purchases and sales
================================================================================================================
Purchase/sale Number of relevant Price per
securities unit (Note
5)
===================== ================================================= ======================================
Purchase 300,000 6.831747
Purchase 200,000 7.175
===================== ================================================= ======================================
(b) Derivatives transactions (other
than options transactions)
================================================================================================================
Product
name, Nature of Number of relevant Price
e.g. CFD transaction securities per unit
(Note 6) (Note 7) (Note
5)
=================== =================== ============================================ ========================
(c) Options transactions in respect
of existing relevant securities
(i) Writing, selling, purchasing
or varying
================================================================================================================
Product Writing, Number Exercise Type, Expiry Option
name, selling, of securities price e.g. date money
e.g. purchasing, to which American, paid/received
call varying the option European per
option etc. relates etc. unit
(Note (Note
7) 5)
================= =================== ================ ============ ============ ======== ================
(ii) Exercising
================================================================================================================
Product name, Number of securities Exercise
e.g. call price per
option unit (Note
5)
===================== ================================================= ======================================
(d) Other dealings (including transactions
in respect of new securities) (Note
4)
================================================================================================================
Nature of Details Price per
transaction unit
(Note 8) (if applicable)
(Note 5)
===================== ================================================= ======================================
1 February 2009
4. OTHER INFORMATION
Agreements, arrangements or understandings
relating to options or derivatives
==============================================
Full details of any agreement, arrangement
or understanding between the person
disclosing and any other person relating
to the voting rights of any relevant
securities under any option referred
to on this form or relating to the
voting rights or future acquisition
or disposal of any relevant securities
to which any derivative referred to
on this form is referenced. If none,
this should be stated.
==============================================
Is a Supplemental Form 8 attached?
(Note 9) YES/NO
==============================================
Date of disclosure 25 January 2012
============================= ===============
Contact name Kelly Morgan
============================= ===============
Telephone number 0207 418 8860
============================= ===============
If a connected EFM, N/A
name of offeree/offeror
with which connected
============================= ===============
If a connected EFM, N/A
state nature of connection
(Note 10)
============================= ===============
1 February 2009
This information is provided by RNS
The company news service from the London Stock Exchange
END
RETLLFSFLIIEFIF
AGI (LSE:AGI)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
AGI (LSE:AGI)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
Real-Time news about AGI (London Stock Exchange): 0 recent articles
Plus d'articles sur Peel Hunt LLP